SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Mexico-EU Free Trade Deal Signals Strategic Shift Away From U.S. Dependence 
JPMorgan Sees Large-Cap Biotech Stocks Entering New Growth Phase in 2026 
Iran-U.S. Talks Continue as Strait of Hormuz and Uranium Dispute Stall Peace Efforts 
Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
Moody’s Downgrades Mexico Credit Rating Amid Rising Debt and Fiscal Pressure 
Trump-China Summit Yields Limited Progress on Trade and Tech Cooperation 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines 
Asian Stocks Slide Ahead of Nvidia Earnings as Tech Shares Tumble 
World Bank Emergency Funding Demand Surges as 27 Countries Seek Crisis Support Amid Iran Conflict 
Dollar Eases as US-Iran Peace Deal Report Impacts Forex and Bond Markets 
US Economy Fueled by AI Investment Faces Rising Risks Ahead of Fed Meeting 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Fed Signals Possible Rate Hikes if Inflation Remains High in 2026 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
